Cancer in the NHS Explained for Medicine Interviews: Record Diagnoses, Screening, Waiting Times and the National Cancer Plan

More than 1,000 people a day were diagnosed with cancer in England in 2024, a record. Earlier diagnosis is improving slowly, but waiting time targets are still missed. For medicine interviews, know why numbers are rising, how screening and early diagnosis work, and what the National Cancer Plan promises.

I'm Dr Akash Gandhi, an NHS GP and the founder of TheUKCATPeople, and I've been helping students prepare for medicine interviews since 2012.

As a GP, I make urgent suspected cancer referrals most weeks. Most of them turn out not to be cancer, and that is how the system is meant to work: a low threshold for referral is how cancers get caught early.

This guide covers the latest figures, what they mean and the questions they lead to. Other current topics are in our NHS hot topics guide.

What do the latest cancer figures for England show?

The latest cancer registration statistics, published in November 2026, cover people diagnosed in 2024. They show the most diagnoses ever recorded in England.

Cancer is common. Cancer Research UK estimates that nearly 1 in 2 people in the UK will be diagnosed with cancer during their lifetime.

Key Takeaway: England diagnosed a record 1,021 people a day with cancer in 2024, and a slightly higher share were caught early.

Is a record number of cancer diagnoses bad news?

This is a favourite interview question, because the answer is "partly, and it depends what is driving it". A rising count can come from several causes, and some of them are good news.

• An ageing population: cancer is mainly a disease of older age, and there are more older people than ever
• A growing population: more people means more diagnoses even if each person’s risk stays the same
• Better detection: more screening and more GP referrals find cancers that might once have been missed or found late
• Lifestyle risk: obesity, alcohol and inactivity raise the risk of several cancers

Researchers separate the raw number from the age-standardised rate, which adjusts for the age of the population. If the count rises but the rate is flat, the main driver is ageing. If the rate rises too, risk is going up.

More diagnoses at an early stage is a sign of success. More diagnoses at a late stage, or in A&E, is a sign the system is struggling. Our guide on how to read a medical paper helps with questions that ask you to interpret data like this.

Key Takeaway: A record count is not automatically bad: ask whether it reflects ageing, better detection or rising risk, and at what stage cancers are found.

Why does early diagnosis matter so much?

Cancers found at stage 1 or 2 are smaller and have not spread, so treatment is more likely to cure them, and is often less intensive. For many cancers, survival is several times higher when they are found at stage 1 than at stage 4.

In 2019 the NHS Long Term Plan set an ambition to diagnose 75% of cancers at stage 1 or 2 by 2028. With 56.7% in 2024, England remains a long way from that goal.

Cancers are found in three main ways:

• Screening: testing people who have no symptoms
• Urgent GP referral: a patient sees their GP with symptoms and is referred for tests
• Emergency presentation: the cancer is found when someone becomes unwell and goes to A&E, often at a later stage

GPs are the gateway for most diagnoses, which is why primary care matters so much in cancer. Cancer symptoms are often vague, such as tiredness or weight loss, and they overlap with common minor illnesses.

Patients sometimes need several GP visits before referral. Jess’s Rule, introduced in 2025 after the death of Jessica Brady, asks GPs to rethink a diagnosis when a patient comes back a third time with the same or worsening symptoms.

Key Takeaway: Early diagnosis is the biggest lever for survival, and England is still well short of its own target.

How does cancer screening work in England?

Screening means testing people who feel well, to find cancer early or to find changes that could become cancer. England runs four cancer screening programmes.

Each programme has its own details on the NHS website: bowel, breast, cervical and lung. Targeted lung screening looks promising: 76% of lung cancers it finds are at stage 1 or 2, compared with 30% outside the programme.

Comparisons like this flatter screening a little. Screening also picks up slow-growing cancers that might never have caused harm, which pushes the early-stage share up. Fewer deaths from the cancer is the fairer test of any programme.

Why not screen for every cancer?

Screening can harm as well as help. In 1968 the World Health Organization published the Wilson and Jungner principles, which still guide decisions. The condition should be an important health problem, there should be a suitable test that people will accept, and treatment should work better when it is started early.

The main harms are false positives, which cause anxiety and invasive tests, and overdiagnosis: finding slow cancers that would never have caused harm, then treating them anyway.

Prostate cancer is the classic example. The PSA blood test can be raised without cancer and normal when cancer is there, and screening all men would find many cancers that never needed treatment.

In the UK, the UK National Screening Committee reviews the evidence and advises ministers on which programmes should run.

Key Takeaway: Screening finds cancer early, but it can also cause harm through false positives and overdiagnosis, so it is only offered where benefits clearly win.

What are the cancer waiting time targets, and is the NHS meeting them?

In October 2023 the NHS replaced the old two week wait with three standards. The Faster Diagnosis Standard measures how quickly patients get an answer, not only how quickly they are first seen.

The latest figures, analysed by Cancer Research UK, show all three standards are still missed. The 62-day standard is the furthest behind and was last met in 2015.

The reasons overlap with wider pressures on the NHS: shortages of radiologists, oncologists and pathologists, not enough scanners, and demand rising faster than capacity. Our guide to NHS backlogs and waiting lists covers the wider picture.

Key Takeaway: Know the 28, 31 and 62 day standards and that all three are missed, with the 62 day target not met since 2015.

What is the National Cancer Plan for England?

The government published the National Cancer Plan for England on 4 February 2026. It sits alongside the 10 Year Health Plan and uses its three shifts: hospital to community, analogue to digital, and treatment to prevention.

Its main commitments are:

• Survival: 3 in 4 people diagnosed in 2035 to be cancer-free or living well with cancer five years later
• Waiting times: all three cancer waiting time standards met by March 2029
• Screening: lung screening across England by 2030, and a more sensitive bowel screening test by 2028
• Early diagnosis: four measures, including the share found at stage 1 or 2, the gap between rich and poor areas and the number diagnosed in emergencies
• Technology: more diagnostic tests in community centres, genomic testing, and AI to help find people at higher risk

Cancer charities welcomed the plan but raised concerns. Cancer Research UK said it lacked detail on funding and staff, and could have gone further on prevention, for example with minimum unit pricing for alcohol.

A fair question is whether this plan will be different. The plan itself admits that earlier cancer strategies, including the 2019 early diagnosis ambition, did not change outcomes enough, and that the 62-day target has been missed for about a decade. Promises are easier to write than to fund.

Key Takeaway: The 2026 plan aims for 3 in 4 people to survive five years by 2035 and for all waiting time targets to be met by 2029.

How can cancer be prevented?

Around 4 in 10 cancers in the UK are thought to be preventable. Prevention fits the third shift of the 10 Year Health Plan, and it is the area where the cancer plan was criticised most.

• Smoking: the biggest preventable cause of cancer; the smoking ban will stop anyone born after 2008 legally buying tobacco
• Obesity: the second biggest preventable cause, linked to at least 13 cancers; see our obesity guide
• Alcohol: linked to cancers including breast, bowel and liver
• HPV vaccination: offered to girls and boys in school, and expected to make cervical cancer rare
• Sun protection: reduces the risk of skin cancer, including melanoma

Key Takeaway: Around 4 in 10 cancers could be prevented, mainly through smoking, weight, alcohol and HPV vaccination, but prevention raises its own questions about how far the state should go.

Why do cancer outcomes differ between groups?

Who you are and where you live affect your chance of getting cancer, how early it is found and how likely you are to survive. People in the most deprived areas are more likely to smoke and to be diagnosed late.

Screening uptake is lower in deprived areas and in some ethnic minority groups. Services also vary between areas, which links to the postcode lottery. The cancer plan includes the gap in early diagnosis between the richest and poorest areas as one of its four measures.

This is a good place to bring in justice as an ethical principle, and the wider causes of ill health set out in our health inequalities guide.

Key Takeaway: Cancer outcomes are worse in deprived areas, so targeted screening and early diagnosis are as much about fairness as survival.

What ethical questions does cancer raise?

Many cancer questions turn into ethics questions. The four pillars of medical ethics give you a structure: autonomy, beneficence, non-maleficence and justice.

Screening and informed choice

Screening is offered, never compulsory. Respecting autonomy means people should understand the possible harms, such as false positives and overdiagnosis, as well as the benefits, before they decide.

Some people choose not to be screened, and that is their right. The NHS still has a duty to make screening easy to reach, especially for groups with low uptake, so that a choice not to attend is a real choice.

Who should be screened for prostate cancer?

In May 2026 the UK National Screening Committee recommended screening only men aged 45 to 61 with a BRCA2 gene change and a family history of cancer, with a PSA test every two years. The government accepted this for England, with rollout expected in 2027, as Cancer Research UK reported.

The debate has two sides:

• For wider screening: prostate cancer is the most common cancer in men, earlier diagnosis could save lives, and Black men and men with a family history are more likely to be diagnosed
• Against wider screening: the PSA test leads to many biopsies and to treatment of harmless cancers, which can cause incontinence and erectile problems
• The evidence: the committee found no clear proof yet that Black men or men with a family history alone are more likely to get fast-growing cancers, so the balance of benefit and harm is uncertain

Should cancer get special treatment?

Cancer has its own waiting time targets and its own Cancer Drugs Fund, which since 2016 has given patients access to promising new drugs while more evidence is collected. Heart failure and dementia also kill large numbers of people, without a dedicated fund.

Supporters argue that cancer is time-critical, so delay costs lives. Critics argue every NHS pound spent one way cannot be spent another, which is why NICE judges drugs by cost-effectiveness. This is a good test of justice and fair resource allocation.

Prevention and personal freedom

Smoking bans, sugar taxes and minimum alcohol pricing could prevent many cancers, but they limit personal choice. Supporters say the state should protect people, especially children and those in poorer areas who are hit hardest. Opponents call it the nanny state.

Key Takeaway: Use the four pillars: informed choice in screening, the balance of harm and benefit, and fairness in how cancer is prioritised against other conditions.

Who looks after a patient with cancer?

Every patient’s treatment is planned by a multidisciplinary team: surgeons, oncologists, radiologists, pathologists, specialist nurses and others meet to agree the best plan. Treatment may combine surgery, chemotherapy, radiotherapy, immunotherapy and targeted drugs.

Doctors often have to share a cancer diagnosis, and interviews test this skill. Our guide to breaking bad news with SPIKES shows how to structure the conversation, step by step.

When cancer cannot be cured, palliative care supports patients and families, often alongside treatment. AI is also being tested to read scans and mammograms faster; our AI in medicine guide covers the debate.

As a GP, I keep looking after patients through treatment and beyond. Many people now live with cancer for years, so the GP often becomes the person who coordinates care.

Key Takeaway: Cancer care is a team effort, from the MDT and specialist nurses to the GP, with good communication at every step.

How can I talk about cancer in my medicine interview?

Cancer comes up in several forms: a current affairs question on the latest figures, a data station, an ethics scenario about screening, or a role-play where you break bad news.

Work experience gives you real examples. A clinic, a ward, a hospice or a day with a GP may show you the MDT, how long patients wait, or how a diagnosis affects a family.

Interviewers look for:

• Accurate facts: a few key numbers you can quote with confidence
• Balanced thinking: you can see both sides, such as the benefits and harms of screening
• Compassion: you remember the patient and family behind every statistic
• Awareness of the system: you understand pressures on staff, scanners and time

For role-plays, our guide to MMI role-play stations shows how to handle a worried patient, and our medicine interview coaching gives you mock stations with personalised feedback.

Key Takeaway: Learn a handful of figures, give balanced views and always bring the discussion back to patients.

Example interview questions on cancer

You are unlikely to be asked any of these word for word, and you do not need a prepared answer to each one. Use them to check your understanding: if you could speak for a minute on most of them, you know this topic well enough for whatever the interviewer actually asks.

Questions to get you thinking

1. Why is the number of cancer diagnoses in England rising?
2. Why does diagnosing cancer early matter?
3. Which cancer screening programmes does the NHS run?
4. What is a multidisciplinary team, and why is it used in cancer care?
5. What did you learn about cancer care from your work experience?

Harder questions to stretch you

1. Should the NHS pay for a cancer drug that extends life by a few months at a very high cost?
2. Is it fair that cancer has its own waiting time targets when other conditions do not?
3. Should the NHS spend more on cancer prevention or on new cancer drugs?
4. A patient with symptoms has seen their GP three times. What should happen next?

Model answer: "Cancer diagnoses have reached a record high. Is that good or bad news for the NHS?"

I think it is partly both, and the headline number on its own does not tell us which. The NHS diagnosed more than 1,000 people a day with cancer in 2024, the highest figure on record.

Some of that rise is expected. Cancer is mainly a disease of older age, and our population is growing and ageing. Some of it reflects better detection, such as lung screening and more urgent GP referrals, which find cancers earlier.

Earlier diagnosis is good news, because those cancers are more likely to be cured. The share found at stage 1 or 2 did rise, to around 57%, but that is still well below the NHS ambition of 75%.

The concern is capacity. More patients need more scans, specialists and treatment, and the NHS is already missing its waiting time targets, especially the 62-day target for starting treatment.

Part of the rise also reflects risk factors like obesity and alcohol, which shows prevention matters as much as treatment.

So I would say the figure is a sign the NHS is finding more cancers, which is positive, but also a warning about demand. Behind each number is a patient and a family waiting for answers, which is why faster diagnosis matters.

Why this answer works:

• It is balanced: it explains why the number rises before judging it
• It uses evidence: a few accurate figures, not a list of statistics
• It ends with patients: it links the data back to the people affected

Model answer: "Should the NHS screen all men for prostate cancer?"

I think the evidence has to decide this, so I would weigh the benefits against the harms.

The case for screening all men sounds strong. Prostate cancer is the most common cancer in men in England, and finding it earlier could mean more men are cured.

But the PSA test has real problems. It can be raised without cancer, leading to worry and biopsies, and it can be normal when cancer is there. It also finds many slow-growing cancers that would never cause harm, and treating those can leave men with incontinence or erectile problems.

That is why the UK National Screening Committee recommended against screening all men in 2026. It did recommend screening men aged 45 to 61 with a BRCA2 gene change and a family history of cancer, because the benefit for them is clearer, and the government accepted this.

I can understand why some charities want more, especially for Black men, who are more likely to be diagnosed. I would want the decision reviewed again as large new trials report.

So for now I would support targeted screening, while making sure any man with symptoms or worries can talk to his GP about a PSA test, after a clear discussion of the pros and cons.

Why this answer works:

• It weighs both sides: benefit and harm before reaching a view
• It knows the current position: the 2026 screening decision, in one sentence
• It stays open: it respects the other side and accepts that evidence can change

Practise more with our medical school practice interview questions and our guide on how to answer medical ethics interview questions.

Key Takeaway: For any data question, explain what drives the number, weigh the good and the bad, then bring it back to patients.

The one thing to take into the room

Cancer touches almost every part of the NHS, from GP surgeries to screening, scanners and specialist teams. If you can explain why diagnoses are rising, why early diagnosis matters and what the NHS is doing about waiting times, you are well prepared.

Key Takeaway: Know the numbers, understand what drives them and keep the patient at the centre of every answer.